Imagine facing not just one, but two life-threatening challenges: HIV and lymphoma. For patients dealing with HIV-associated lymphoma, treatment options can be limited and complex. This study explores a new approach that combines a unique immune therapy called HST-NEETs with a bone marrow transplant. Participants in this trial had their blood collected to create these specialized immune cells, which are designed to target the cancer while also addressing the underlying HIV. The goal is to see how many patients can receive this therapy soon after their transplant and how effective it is in reducing HIV levels in the body. If successful, this could mean a significant breakthrough for patients who often feel they have few options left. However, it’s important to note that this is still in the testing phase, and more research is needed to fully understand the benefits and risks. As we look ahead, this innovative approach brings a glimmer of hope for those facing the dual challenges of HIV and lymphoma.
Can a New Treatment Help Patients with HIV-Related Lymphoma Beat the Odds?
Plain Language Summary
What this means for you:
A new treatment combining immune therapy and bone marrow transplant may offer hope for HIV-related lymphoma patients. What this means for you:
A new treatment combining immune therapy and bone marrow transplant may offer hope for HIV-related lymphoma patients. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): HIV Associated Lymphoma
Intervention(s): HST-NEETs (BIOLOGICAL), Bone Marrow Transplant (BIOLOGICAL)
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Detailed: Eligible participants will have 100-120 mL of peripheral blood or 80-100 mL of MNCs via apheresis collected and shipped to Children's National Hospital at ambient temperature. The sample will be used to manufacture the HST-NEET product. The autologous peripheral blood stem cell graft suitable for rescue following conditioning will be obtained either before or after the collection of blood to generate HST-NEETs. Pre-transplant conditioning will consist of BEAM; BCNU 300 mg/m\^2 on Day -6, Etoposide 100 mg/m\^2 BID and Ara-C 100 mg/m2 BID on Days -5, -4, -3 and -2 and Melphalan 140 mg/m2 on Day -1. ASCT on Day 0. If the mobilized graft contains greater than 5.0 x 106 CD34+ cells per kg, any additional cells should be cryopreserved as a "back-up" graft in the event of graft failure related to
Primary Outcome(s): To determine 1.) the proportion of participants who can be treated with (HST-NEETs) within 1 week of ASCT in a cooperative multi-institutional setting and 2.) the efficacy of HSTNEETs in reducing the HIV intact proviral
Enrollment: 12 (ACTUAL)
Lead Sponsor: Catherine Bollard
Start: 2021-10-25 | Primary Completion: 2025-11-24